Synonyms: IBI 308 | IBI-308 | IBI308 | Tyvyt®
sintilimab is an approved drug (China (2018))
Compound class:
Antibody
Comment: Sintilimab (IBI 308) is a fully human IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody [5]. It acts as an immune checkpoint inhibitor and is used clinically as an immuno-oncology therapeutic.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
No information available. |
Summary of Clinical Use ![]() |
Sintilimab (IBI 308) was granted first approval in China in December 2018, to treat relapsed/refractory classical Hodgkin's lymphoma [2].Elsewhere it is in advanced clinical evaluation as an immunotherapy for solid tumours and haematological malignancies. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05171660 | Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | Phase 3 Interventional | Second Affiliated Hospital, School of Medicine, Zhejiang University | 1 | |
NCT04277663 | The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery | Phase 3 Interventional | Innovent Biologics (Suzhou) Co. Ltd. | ||
NCT03150875 | A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC | Phase 3 Interventional | Innovent Biologics (Suzhou) Co. Ltd. | ||
NCT03802240 | Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | Phase 3 Interventional | Innovent Biologics (Suzhou) Co. Ltd. | ||
NCT03114683 | Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma | Phase 2 Interventional | Innovent Biologics (Suzhou) Co. Ltd. | 3 | |
NCT03745170 | Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer | Phase 3 Interventional | Innovent Biologics (Suzhou) Co. Ltd. | 4 |